Navigation Links
Tolerx Presents Preclinical Data on Novel Cancer Immunotherapeutic, TRX518, a First-in-Class Anti-GITR Antibody
Date:2/9/2011

iabetes, and cancer by normalizing the immune system. The company's pipeline includes its lead candidate, otelixizumab, a targeted T cell immunomodulator in Phase 3 development for the treatment of type 1 diabetes that is partnered with GlaxoSmithKline. Tolerx's product candidate, TRX518, is a targeted T cell immunotherapy in Phase 1 development for the treatment of cancer. TRX1, a Phase 1 candidate, is a nonlytic anti-CD4 antibody that is being developed for the treatment of aberrant or untoward immune responses. The company also has two preclinical candidates, TRX585 and TRX385, which enhance immune responses and as such are being evaluated for potential benefit in the treatment of cancer and chronic infections. Tolerx is a privately held company headquartered in Cambridge, MA USA. For more information, please visit www.tolerx.com.


'/>"/>
SOURCE Tolerx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Tolerx Appoints Antonin de Fougerolles, Ph.D., as Chief Scientific Officer
2. Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes
3. Tolerx Presents Baseline Data from DEFEND-1 Study Validating C-Peptide as Critical Clinical Measure for New-Onset Type 1 Diabetes
4. Tolerx Presents Preclinical Data on Novel T-cell Modulator, TRX518, for Antitumor Immune Response at Federation of Clinical Immunology Societies Scientific Meeting
5. Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
6. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
7. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
8. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
9. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
10. Prime Therapeutics President and CEO Eric Elliott Presents Keynote Address at 2011 PCMA Managed Markets Educational Forum
11. Watson Presents Outlook for Continued Long Term Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... Inc. (Nasdaq: SMLR ), a company that provides ... groups, today reported financial results for the second quarter ... second quarter of 2015, Semler reported continued progress with ... quarter revenue growth of 8%, and quarter over quarter ... 18%," said Doug Murphy-Chutorian, M.D., chief executive officer of ...
(Date:7/31/2015)... July 31, 2015  Xencor, Inc. (NASDAQ: XNCR ... for the treatment of autoimmune diseases, asthma and allergic ... Yujiro S. Hata to its board of directors. ... and corporate development is a tremendous asset to our ... chief executive officer of Xencor. "Xencor faces a range ...
(Date:7/31/2015)... , July 31, 2015 ... solutions for video, data and cloud computing operators ... a leading pharma giant for Internet of Things ... IoT applications offered on subscription model. ... Pharma giant is striving for business innovations to ...
Breaking Medicine Technology:Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2
... HORSHAM, Pa., Sept. 20, 2011 Verilogue, the ... upcoming presentations highlighting company initiatives, including CareCoach.com, the ... healthcare dialogue between patients, caregivers and their physicians. ... conferences in September: e-Patient Connections; ...
... Sept. 20, 2011 Reportlinker.com announces that a ... catalogue: Rheumatoid Arthritis Market Forecast ... The launch of novel oral drugs and reformulations ... across the seven major markets, rising from $12bn ...
Cached Medicine Technology:Verilogue to Present at Upcoming Health IT and Patient-Focused Conferences 2Rheumatoid Arthritis Market Forecast 2
(Date:7/31/2015)... ... July 31, 2015 , ... Indosoft, Inc., is pleased ... in Q-Suite 5.9. Q-Suite is their flagship contact center ACD system for Asterisk-based ... script display logic shows the script components to the agent only when wanted, and ...
(Date:7/31/2015)... ... July 31, 2015 , ... According to WFLA on ... of heroin use and eventual overdoses. Thricefold deaths have held steady over the last ... on the Sarasota heroin epidemic, which was spurred by the crackdown of prescription painkillers. ...
(Date:7/31/2015)... GA (PRWEB) , ... July 31, 2015 , ... ... Practice, Pediatric Emergency Medicine Practice, and Hospital Medicine Practice, is pleased to announce ... in a mobile application format available on iPhones, iPads, and Android smartphones ...
(Date:7/31/2015)... ... July 31, 2015 , ... An article entitled " ... about a woman’s unfortunate experience having cosmetic skin procedures done by a family ... in blistering, swelling, bruising, and pain. This woman’s experience is only one in ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... a wide variety of nutritional and wellness products, announced the addition of Vincent ... in massage therapy, active isolated stretching and the prevention and rehabilitation of injuries, ...
Breaking Medicine News(10 mins):Health News:Q-Suite 5.9 Adds Validation Tools to Call Center Software Agent Screen 2Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 2Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 3Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 2Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 3Health News:Dermatologists Discuss Rise in Unqualified Practitioners of Cosmetic Dermatology 2Health News:Dermatologists Discuss Rise in Unqualified Practitioners of Cosmetic Dermatology 3Health News:NPI Welcomes Vincent Aquilino to Board of Directors 2
... a large multi-center clinical trial, a new PSA test ... with prostate cancer -- particularly the aggressive form of ... to the two,currently available commercial PSA tests, according to ... currently available Food and Drug Administration-approved screening tests for ...
... Research institutions at 27 sites in the U.S. ... Cancer Immunotherapy Trials Network (CITN), a new initiative in ... at Fred Hutchinson Cancer Research Center. CITN will establish ... research on promising new agents that boost patients, own ...
... Mo. - Youths identified as American Indian or Alaska ... all racial groups, according to the Department of Health ... AI/AN youths in the U.S. smoke cigarettes. A University ... combat smoking should teach refusal skills to help youths ...
... , WEDNESDAY, April 6 (HealthDay News) -- Poor children with ... condition diagnosed, but this disparity has decreased in recent years, ... children in California and found that the average age of ... 1992 to 3.8 years for those born in 2000. ...
... , WEDNESDAY, April 6 (HealthDay News) -- Progesterone treatment lowers ... cervix, a new study shows. Progesterone is a naturally ... It,s believed that a short cervix -- a known risk ... a shortage of progesterone. This study included 458 women ...
... April 5 White House Press Briefing, President Barack Obama articulated ... Congress from both political parties in order to avoid a ... has matched the initial House of Representatives, proposal to make ... in areas of priority. He expressed that neither side would ...
Cached Medicine News:Health News:New prostate cancer test gives more accurate diagnosis 2Health News:Fred Hutchinson Cancer Research Center to lead Immunotherapy Clinical Trials Network 2Health News:Fred Hutchinson Cancer Research Center to lead Immunotherapy Clinical Trials Network 3Health News:Fred Hutchinson Cancer Research Center to lead Immunotherapy Clinical Trials Network 4Health News:Refusal skills help minority youths combat smoking, study finds 2Health News:Autism Diagnoses Still More Likely in Richer Neighborhoods 2Health News:Progesterone Treatment Cuts Preterm Birth Risk in Certain Women 2Health News:AADR applauds President Obama's support for maintaining biomedical research in FY11 2
... needed for quality, comprehensive portable and bedside ... allows you to see up to four ... touch screen allows easy navigation through menus ... temperature., ,Standard features include two channels ...
... all-in-one anesthesia monitor., ,The Cardiocap/5 ... for use in the operating room, ... PACU. The Cardiocap/5 offers full vital ... of oxygenation and circulation to advanced ...
... tool for Clinical Professionals and Researchers., ,S/5 ... easy and efficient way to collect data from ... to days at selectable time intervals. With S/5 ... from the monitor via an interface cable or ...
... for intermediate care., ,The S/5 FM is ... S/5 product line., ,The S/5 FM has ... to grow. The new Patient Side Module (PSM) ... up to 12-lead ECG, NIBP, motion-tolerant SpO 2 ...
Medicine Products: